Opendata, web and dolomites

EVEREST SIGNED

Extracellular Vesicles for Bone Regeneration – alternatives to Stem-cell Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EVEREST project word cloud

Explore the words cloud of the EVEREST project. It provides you a very rough idea of what is the project "EVEREST" about.

benefits    heterogeneity    tested    progressing    everest    replacements    lipids    msc    extracellular    potent    elasticity    tumors    responsible    donors    collection    vivo    soluble    medicine    culture    revolutionize    modulate    secretome    harnessing    breaking    induce    cell    sustained    intelligent    therapies    release    trauma    cargo    environment    platform    metabolic    chromatography    3d    stem    correct    harvest    resection    exclusion    free    mesenchymal    firstly    treatment    potency    nucleic    answer    constructs    transport    replaced    defects    marrow    anatomically    healing    mechanical    shelf    diseases    answering    regeneration    ground    hypothesis    favorable    hypoxia    delineate    size    human    critical    proteins    regenerative    mscs    evs    nanoparticles    therapeutic    questions    elimination    pain    printing    edge    secreted    cutting    stress    cells    functionalized    handle    embark    off    separates    manner    fabricated    hypotheses    vesicles    therapy    attributed    bone    dynamic    permit    ev    cancerous    acids    substrate    employed    reduce    reported    frontier    cues    bioactive    environments   

Project "EVEREST" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙499˙925 €
 EC max contribution 1˙499˙925 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙499˙925.00

Map

 Project objective

The therapeutic benefits of mesenchymal stem cells (MSCs), the state-of-the-art treatment for healing bone defects following trauma, resection of cancerous bone tumors, or metabolic bone diseases, has been attributed to their secreted factors. The regenerative potential of MSC-secreted extracellular vesicles (EVs), nanoparticles which deliver bioactive cargo (nucleic acids, proteins, and lipids) between cells, has recently been reported. The applicant will embark upon frontier research with the objective of progressing beyond the state-of-the-art, by harnessing the therapeutic effects of MSCs, but in a cutting-edge, cell-free manner, by developing high potency EV-based bone replacements. This objective will be addressed by firstly testing novel hypotheses to delineate how culture environments, specifically mechanical cues (substrate elasticity and 3D dynamic), hypoxia, and cell stress can modulate the cargo of EVs secreted by MSC. Size exclusion chromatography, which separates EVs from soluble proteins will be employed. Heterogeneity of EV cargo and functionality between human MSC donors will also be evaluated. Answering these hypotheses will permit the intelligent design of targeted EV therapies. The hypothesis that EV-functionalized constructs, fabricated by 3D-printing, will lead to controlled and sustained release of EVs and induce bone formation in vivo will best tested. Together, this will answer critical questions, namely the most favorable environment for collection of potent EVs for regenerative medicine, which secretome component (EV, soluble factors) is responsible for bone regeneration, and whether MSC cell therapy can be replaced by cell-free EVs. EVEREST will develop a platform for targeted EV delivery in ground-breaking, easy to transport and handle, ‘off-the-shelf’ anatomically correct constructs, which have the potential to reduce pain by elimination of bone or bone marrow harvest, and revolutionize the treatment of bone defects.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVEREST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVEREST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More